2023 ASA Anesthesia Practice Guidelines for Monitoring Neuromuscular Blockade: December 2022 guideline summary: Patients monitored quantitatively had less residual neuromuscular blockade compared to patients assessed qualitatively or clinically. For information on quantitative TOF monitors options contact Bell Medical at [email protected]
Jerry Keeton closed a sale on 27 Xavant Stimpod 450X to Cox Medical Center in Kansas City, MO. Dan Hogan also closed a deal on Heine Easy Clean Handles and Heine blades to Rhode Island Hospital in Providence, RI.
The Stimpod NMS450X NMT monitor for Anesthesia first to feature both AMG and EMG modalities in one single, portable patient monitoring system. Pretoria, South Africa, October. 15, 2019 – Xavant Technology, a pioneer in neuromuscular monitoring and innovative neuromodulation modalities, announced an addition to the company’s newest generation of Stimpod neuromuscular transmission monitor – the … Read more
Some sort of assessment of neuromuscular transmission (NMT) is necessary in surgical patients by clinicians and anesthetists to get a feel for the depth of anesthesia. This assessment can be done using simple yet subjective clinical parameters or through more advanced and objective monitoring devices. NMT monitoring is required to ascertain that anesthesia is appropriate … Read more
Respiratory impairment following general anaesthesia can pose a significant problem. Adverse and critical respiratory events (AREs and CREs) have been responsible for increased morbidity and mortality. The main cause of AREs after surgery is related to the use of neuromuscular blockers (NMBAs) during general anaesthesia. The action of NMBAs might not cease completely at the … Read more
Postoperative residual curarization (PORC), also known as residual neuromuscular blockade, refers to the residual muscle paralysis that occurs after emergence from general anesthesia. PORC stems from the use of neuromuscular blocking agents (NMBAs). It is defined as a Train-of-Four (TOF) ratio of <0.9 and may occur in around 41% of patients who receive intermediate-acting neuromuscular … Read more
PRETORIA, South Africa, Aug. 1, 2017 /PRNewswire/ — Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, … Read more
The German manufacturer, MIPM – Mammendorfer Institut für Physik und Medizin GmbH has announced that effective June 30, 2016 the TOF Watch, TOF Watch S and TOF Watch SX neuromuscular monitors will no longer be manufactured. The official announcement of the discontinuance of the TOF Watch is below: TOF-Watch – objective neuromuscular monitoring Product cancelation … Read more